Elena Schonlau

Vancouver, BC, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Journal: Nature communications

Published: October 09, 2025

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.

Journal: Nature communications

Published: July 21, 2023

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes.

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes.

Journal: NPJ precision oncology

Published: November 12, 2022

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.

Journal: Nature cancer

Published: September 30, 2022

Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.

Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.

Journal: JCO precision oncology

Published: May 04, 2022

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.

Journal: Nature

Published: November 13, 2021

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 09, 2020

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 18, 2020

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.

Journal: European urology

Published: January 20, 2020

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.

Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 17, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026